JP7634934B2 - β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用 - Google Patents

β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用 Download PDF

Info

Publication number
JP7634934B2
JP7634934B2 JP2019547093A JP2019547093A JP7634934B2 JP 7634934 B2 JP7634934 B2 JP 7634934B2 JP 2019547093 A JP2019547093 A JP 2019547093A JP 2019547093 A JP2019547093 A JP 2019547093A JP 7634934 B2 JP7634934 B2 JP 7634934B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
hours
pharma
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019547093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510661A (ja
JP2020510661A5 (enExample
Inventor
ジェイ． バーンズ，クリストファー
シー． ペベア，ダニエル
ゼリー，ルイージ
ヘンケル，ティモシー
マクギャリー，ダニエル
ローゼン，ローレンス
ブレナー，ジェラルド
アーリン，ジャン―バプティスト
カサレス，アナ フェルナンデス
Original Assignee
ベナトルクス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベナトルクス ファーマシューティカルズ，インク． filed Critical ベナトルクス ファーマシューティカルズ，インク．
Publication of JP2020510661A publication Critical patent/JP2020510661A/ja
Publication of JP2020510661A5 publication Critical patent/JP2020510661A5/ja
Priority to JP2023007546A priority Critical patent/JP2023061946A/ja
Application granted granted Critical
Publication of JP7634934B2 publication Critical patent/JP7634934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019547093A 2017-03-06 2018-03-05 β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用 Active JP7634934B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023007546A JP2023061946A (ja) 2017-03-06 2023-01-20 β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762467750P 2017-03-06 2017-03-06
US201762467752P 2017-03-06 2017-03-06
US62/467,752 2017-03-06
US62/467,750 2017-03-06
US201762564989P 2017-09-28 2017-09-28
US201762564990P 2017-09-28 2017-09-28
US62/564,989 2017-09-28
US62/564,990 2017-09-28
PCT/US2018/020968 WO2018165048A1 (en) 2017-03-06 2018-03-05 Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023007546A Division JP2023061946A (ja) 2017-03-06 2023-01-20 β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Publications (3)

Publication Number Publication Date
JP2020510661A JP2020510661A (ja) 2020-04-09
JP2020510661A5 JP2020510661A5 (enExample) 2021-04-08
JP7634934B2 true JP7634934B2 (ja) 2025-02-25

Family

ID=63448038

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019547093A Active JP7634934B2 (ja) 2017-03-06 2018-03-05 β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用
JP2023007546A Pending JP2023061946A (ja) 2017-03-06 2023-01-20 β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023007546A Pending JP2023061946A (ja) 2017-03-06 2023-01-20 β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Country Status (17)

Country Link
US (4) US11091505B2 (enExample)
EP (1) EP3592362B1 (enExample)
JP (2) JP7634934B2 (enExample)
KR (1) KR102603489B1 (enExample)
CN (2) CN117398398A (enExample)
AU (1) AU2018230991B2 (enExample)
BR (1) BR112019018447A2 (enExample)
CA (1) CA3055253A1 (enExample)
ES (1) ES3015371T3 (enExample)
HR (1) HRP20250459T1 (enExample)
IL (2) IL268981B2 (enExample)
MA (1) MA47743A (enExample)
MY (1) MY196966A (enExample)
PH (1) PH12019502037B1 (enExample)
PL (1) PL3592362T3 (enExample)
SG (1) SG11201908181XA (enExample)
WO (1) WO2018165048A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2893943C (en) 2012-12-07 2021-03-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3882252B1 (en) 2014-06-11 2025-11-19 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
PH12019502037B1 (en) 2017-03-06 2024-06-05 Everest Medicines Singapore Pte Ltd Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US20220054513A1 (en) * 2018-09-12 2022-02-24 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519726A (ja) 2004-01-26 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の、新規結晶形態
JP2015508801A (ja) 2012-02-29 2015-03-23 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 抗ウイルス活性ジヒドロキナゾリン誘導体を含有する医薬組成物
JP2016502973A (ja) 2012-12-07 2016-02-01 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021454A (en) 1911-01-23 1912-03-26 Thomas Ernest Davis Serving-table.
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
NZ550522A (en) 2004-03-30 2010-08-27 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
CN1965838A (zh) * 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
BRPI0820532A2 (pt) 2007-11-13 2012-07-10 Protez Pharmaceuticals Inc inibidores de beta-lactamase
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
JP5038509B2 (ja) 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
AU2011373912B2 (en) * 2011-07-26 2016-09-29 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
JP5798495B2 (ja) 2012-01-13 2015-10-21 住友理工株式会社 配線体接続構造体
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
JP6324409B2 (ja) 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015051101A1 (en) * 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
EP3882252B1 (en) 2014-06-11 2025-11-19 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361107A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
EP3189841B1 (en) 2014-09-04 2023-11-22 Shionogi & Co., Ltd. Pharmaceutical preparation comprising cephalosporin having catechol groups
US10364257B2 (en) 2014-12-19 2019-07-30 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
JP7060245B2 (ja) 2016-06-30 2022-04-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
PH12019502037B1 (en) 2017-03-06 2024-06-05 Everest Medicines Singapore Pte Ltd Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US20220054513A1 (en) 2018-09-12 2022-02-24 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
AU2019386849B2 (en) 2018-11-29 2025-07-24 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519726A (ja) 2004-01-26 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の、新規結晶形態
JP2015508801A (ja) 2012-02-29 2015-03-23 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 抗ウイルス活性ジヒドロキナゾリン誘導体を含有する医薬組成物
JP2016502973A (ja) 2012-12-07 2016-02-01 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
創薬段階における原薬Formスクリーニングと選択、PHARM STAGE、２００７年、６（１０）、ｐ．２０～２５
最新 創薬化学 下巻、１９９９年、株式会社テクノミック、ｐ．３４７～３６５
有機化合物結晶作製ハンドブック －原理とノウハウ－、２００８年、丸善株式会社、ｐ．５７～８４
溶剤ハンドブック、株式会社講談社、１９８５年、ｐ．４７～５１
第４版実験化学講座１基本操作Ｉ、１９９６年、丸善株式会社、ｐ．１８４～１８９

Also Published As

Publication number Publication date
CN117398398A (zh) 2024-01-16
US12187752B2 (en) 2025-01-07
IL268981A (en) 2019-10-31
CA3055253A1 (en) 2018-09-13
AU2018230991A1 (en) 2019-09-19
US20220002322A1 (en) 2022-01-06
MY196966A (en) 2023-05-15
SG11201908181XA (en) 2019-10-30
JP2020510661A (ja) 2020-04-09
CN110678186A (zh) 2020-01-10
US11091505B2 (en) 2021-08-17
JP2023061946A (ja) 2023-05-02
EP3592362A4 (en) 2020-09-02
US20200010485A1 (en) 2020-01-09
EP3592362B1 (en) 2025-02-19
ES3015371T3 (en) 2025-05-05
BR112019018447A2 (pt) 2020-04-14
PL3592362T3 (pl) 2025-06-23
AU2018230991B2 (en) 2023-07-13
KR20190117790A (ko) 2019-10-16
MA47743A (fr) 2020-01-15
IL301591A (en) 2023-05-01
US11820784B2 (en) 2023-11-21
EP3592362A1 (en) 2020-01-15
US20240101580A1 (en) 2024-03-28
IL268981B2 (en) 2023-09-01
IL301591B1 (en) 2025-11-01
IL268981B1 (en) 2023-05-01
US20250320235A1 (en) 2025-10-16
EP3592362C0 (en) 2025-02-19
PH12019502037A1 (en) 2020-03-09
WO2018165048A1 (en) 2018-09-13
KR102603489B1 (ko) 2023-11-16
PH12019502037B1 (en) 2024-06-05
HRP20250459T1 (hr) 2025-06-06

Similar Documents

Publication Publication Date Title
JP7634934B2 (ja) β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用
US10189833B2 (en) Solid forms of a compound modulating kinases
TWI846166B (zh) {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
CN117285513A (zh) Hiv衣壳抑制剂的胆碱盐形式
US11524939B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
JP2023550428A (ja) インテグリン阻害剤およびその使用
CA2970926A1 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN102933205B (zh) 西洛他唑共晶和组合物
US7423040B2 (en) Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) Bifeprunox mesylate maintenance dose compositions and methods for using the same
HK40020554A (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
HK40020554B (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EA048377B1 (ru) Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения
EA042812B1 (ru) Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения
HK40013654A (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP4649079A1 (en) Polymorphs of the hydrobromide salt of linaprazan glurate
CN117157078A (zh) 头孢布烯给药方案
TW201029981A (en) Tianeptine sulfate salt forms and methods of making and using the same
HK1248223A1 (en) Solid forms of a compound modulating kinases
HK1248223B (en) Solid forms of a compound modulating kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220920

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230120

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20230201

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250212

R150 Certificate of patent or registration of utility model

Ref document number: 7634934

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150